Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

L Gervaso, H Dave, AA Khorana - Cardio Oncology, 2021 - jacc.org
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

Mechanisms and biomarkers of cancer-associated thrombosis

AS Kim, AA Khorana, KR McCrae - Translational Research, 2020 - Elsevier
Cancer-associated thrombosis is a leading cause of non-cancer death in cancer patients
and is comprised of both arterial and venous thromboembolism (VTE). There are multiple …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology

MB Streiff, B Holmstrom, D Angelini, A Ashrani… - Journal of the National …, 2021 - jnccn.org
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update

NS Key, AA Khorana, NM Kuderer, K Bohlke… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

I Pabinger, N van Es, G Heinze, F Posch… - The Lancet …, 2018 - thelancet.com
Background Venous thromboembolism is a common complication of cancer, but the risk of
developing venous thromboembolism varies greatly among individuals and depends on …

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay… - The Lancet …, 2019 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …

A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective …

A Muñoz, C Ay, E Grilz, S López, C Font… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with
cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with …

[HTML][HTML] Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity

A Falanga, M Marchetti - Journal of Thrombosis and Haemostasis, 2023 - Elsevier
Thrombosis, both venous and arterial, is a leading cause of morbidity and mortality in
patients with cancer. Studies on the molecular basis of cancer-associated thrombophilia …

Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems

A Li, J La, SB May, D Guffey, WL da Costa Jr… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …